Business Context and Reporting Period
This Form 8-K Current Report was filed by Akebia Therapeutics, Inc. on January 30, 2026, covering events occurring on January 27 and January 28, 2026. The filing details the entry into a material definitive lease agreement for new corporate headquarters and laboratory space in Waltham, Massachusetts, and the execution of amended executive severance agreements for the CEO and CFO.
Key Financial Metrics and Obligations
The filing does not provide revenue, profit, cash flow, or margin data. It discloses specific financial obligations related to the new lease and executive compensation:
- Lease Security Deposit: $810,515.00 (irrevocable letter of credit).
- Office Premises Rent: Starting annual rent of $898,317, increasing by $1.00 per square foot annually.
- Lab Premises Rent: Starting annual rent of $1,046,920, increasing by approximately 3.0% annually.
- Lease Term: Initial term of 84 months (7 years) with an option to extend for an additional five years.
Material Changes and Agreements
Headquarters Relocation
The Company entered into a lease for approximately 43,474 square feet (28,518 sq. ft. office, 14,956 sq. ft. lab) at 180 Third Avenue, Waltham, MA. The Company intends to relocate its headquarters in September 2026, coinciding with the expiration of its current Cambridge lease on September 11, 2026. The Landlord is responsible for all costs associated with completing the necessary work on the premises prior to occupancy.
Executive Severance Agreements
The Board approved amended severance agreements for CEO John P. Butler and CFO Erik J. Ostrowski to align with market practices.
- CEO (John P. Butler):
- Standard Termination: 12 months base salary, 100% target bonus, 12 months COBRA reimbursement, and continued equity vesting.
- Change in Control Termination: 24 months base salary, 200% target bonus, 24 months COBRA reimbursement, and immediate vesting of pre-effective date equity.
- CFO (Erik J. Ostrowski):
- Standard Termination: 12 months base salary, 12 months COBRA reimbursement, and continued equity vesting (no bonus specified).
- Change in Control Termination: 12 months base salary, 100% target bonus, 12 months COBRA reimbursement, and immediate vesting of pre-effective date equity.
Outlook, Risks, and Contingencies
The filing indicates a strategic move to consolidate operations in Waltham, MA, with occupancy expected in late 2026. The amended severance agreements introduce significant contingent liabilities tied to a "Change in Control" or termination without cause/for good reason. All severance payments are conditioned upon the executives executing a general release of claims and complying with restrictive covenants.
Investor Verification Checklist
- Verify the total projected cost of the new lease over the 84-month initial term, including estimated operating expenses (taxes, insurance, maintenance).
- Confirm the Company's current cash position to ensure it can fund the $810,515 security deposit and the upcoming rent escalations.
- Review the specific definitions of "Cause," "Good Reason," and "Change in Control" in the attached exhibits (99.1 and 99.2) to assess the likelihood of triggering severance payouts.
- Monitor the timeline for the Landlord's completion of office and lab work to ensure the September/November 2026 occupancy dates are met.